Valuation : Madrigal Pharmaceuticals, Inc.

Market Cap 12.45B 10.69B 10.01B 9.16B 17.26B 1,189B 17.31B 118B 46.32B 599B 46.74B 45.74B 1,983B P/E 2026 *
-85.3x
P/E 2027 * 85.6x
Enterprise Value 11.93B 10.24B 9.58B 8.78B 16.53B 1,139B 16.58B 113B 44.37B 574B 44.78B 43.81B 1,900B EV / Sales 2026 *
7.81x
EV / Sales 2027 * 5.36x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.83%
1 week+4.69%
Current month+16.28%
1 month-1.42%
3 months+2.98%
6 months+25.79%
Current year-6.68%
1 week 506.29
Extreme 506.29
550.33
1 month 447.01
Extreme 447.01
561.15
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.63
Extreme 9.63
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+4.69%+27.85%+200.51% 12.45B
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.23% 65.4B
-0.74%+0.94%+8.66%-7.25% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-1.64%-2.23%-9.10%+465.63% 27.16B
+0.37%+1.21%+36.55%-17.60% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.77%+2.57%+43.00%+148.29% 13.9B
Average +0.28%+1.02%+54.96%+194.10% 30.08B
Weighted average by Cap. +0.84%+0.68%+54.32%+157.39%

Financials

2026 *2027 *
Net sales 1.53B 1.31B 1.23B 1.12B 2.12B 146B 2.12B 14.52B 5.68B 73.47B 5.73B 5.61B 243B 2.14B 1.84B 1.72B 1.58B 2.97B 205B 2.98B 20.41B 7.98B 103B 8.05B 7.88B 342B
Net income -184M -158M -148M -135M -255M -17.56B -256M -1.75B -684M -8.85B -690M -675M -29.29B 200M 172M 161M 147M 277M 19.1B 278M 1.9B 744M 9.63B 751M 735M 31.86B
Net Debt -525M -450M -422M -386M -727M -50.1B -729M -4.99B -1.95B -25.25B -1.97B -1.93B -83.56B -943M -810M -758M -694M -1.31B -90.08B -1.31B -8.98B -3.51B -45.4B -3.54B -3.46B -150B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
28/08/26 US$543.24 +0.81% 127,169
26/08/26 US$538.88 +5.22% 345,540
25/08/26 US$512.16 +0.04% 189,200
24/08/26 US$511.97 -0.92% 145,523
21/08/26 US$516.74 -0.45% 179,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
538.88USD
Average target price
678.06USD
Spread / Average Target
+25.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock